M. Miles Braun

University of Connecticut — United States

Social Sciences · Social Sciences

44h-index11.5kcitations100works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Vaccine Coverage and Hesitancy(28), Influenza Virus Research Studies(16), Pneumonia and Respiratory Infections(10), Pharmacovigilance and Adverse Drug Reactions(9), Pharmaceutical studies and practices(9)

Publications99 total

IgG4-related hypophysitis and AVP-deficiency: A unique presentation and literature review
Neuroimmunology Reports·2025· 1 citedOpen Access
Answering Key Questions About COVID-19 Vaccines
JAMA·2020· 36 cited
Vaccine Safety Surveillance
2014· 2 cited
Temporary Practice Pause Then Resumption (TPPR) Study Design: An Extension of the Withdrawal Study Design to Complementary and Alternative Medicine Mind and Body Interventions (CAM-MABI)
The Journal of Alternative and Complementary Medicine·2013· 2 citedOpen Access
Measles-Mumps-Rubella Vaccine in the United States Prevalence of Anti-Gelatin IgE Antibodies in People With Anaphylaxis After
2013
Characteristics of orphan drug applications that fail to achieve marketing approval in the USA
Drug Discovery Today·2010· 39 cited
Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children
The Pediatric Infectious Disease Journal·2010· 16 cited
Evaluation of Guillain-Barré Syndrome Among Recipients of Influenza Vaccine in 2000 and 2001
American Journal of Preventive Medicine·2010· 57 cited
Therapies for Inborn Errors of Metabolism: What Has the Orphan Drug Act Delivered?
PEDIATRICS·2010· 25 cited
Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years
Nature Reviews Drug Discovery·2010· 148 cited
Orphan products: an emerging trend in drug approvals
Nature Reviews Drug Discovery·2009· 36 citedOpen Access
Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
Obstetrical & Gynecological Survey·2009· 43 cited
Active Influenza Vaccine Safety Surveillance
Medical Care·2009· 24 cited
Kawasaki Disease After Vaccination
The Pediatric Infectious Disease Journal·2009· 57 cited
What Should an Ideal Vaccine Postlicensure Safety System Be?
American Journal of Public Health·2009· 44 citedOpen Access
HLA type and immune response to <i>Borrelia burgdorferi</i> outer surface protein a in people in whom arthritis developed after Lyme disease vaccination
Arthritis & Rheumatism·2009· 46 citedOpen Access
Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990–2007
Vaccine·2008· 29 cited
Adverse event reports following yellow fever vaccination
Vaccine·2008· 277 cited
Potential population‐based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans
Pharmacoepidemiology and Drug Safety·2008· 16 cited
Monitorización de la invaginación tras la autorización de la vacuna RotaTeq en Estados Unidos, 1-2-2006/25-9-2007
PEDIATRICS·2008· 1 cited
page 1 of 5Next →

Frequent Co-authors

Robert Ball(17), Robert T. Chen(10), Emily Jane Woo(7), Jeffrey Siegel(6), Penina Haber(6), Gina T. Mootrey(6), Susan S. Ellenberg(6), John Iskander(6), Sharon K. Gershon(5), Robert P. Wise(5), Evelyne T. Edwards(5), Timothy R. Coté(5), Héctor S. Izurieta(5), S. Michael Marcy(4), Sean V. Shadomy(4), Harald Heijbel(4), Marcel E. Salive(4), Dale R. Burwen(4), Nancy R. Slifman(3), Frank DeStefano(3)